Lilly to divest Baqsimi, nasally administered glucagon, to Amphastar Pharma.
In an effort to continue expanding the availability of Baqsimi to patients, Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. have entered into a definitive agreement for Lilly to divest Baqsimi worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product
Baqsimi is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes. Amphastar expects to provide dedicated commercial investment for Baqsimi with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
Lilly launched Baqsimi in 2019 as an option to quickly render aid in rescue situations for people with diabetes who take insulin and it is currently available in 27 international markets. Worldwide sales for Baqsimi totaled $139.3 million in 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins